MLTX vs. MRNA, QGEN, ASND, ROIV, RVMD, BBIO, BPMC, ELAN, LEGN, and TGTX
Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Moderna (MRNA), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.
MoonLake Immunotherapeutics vs.
Moderna (NASDAQ:MRNA) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.
Moderna has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.
Moderna received 144 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 81.82% of users gave MoonLake Immunotherapeutics an outperform vote while only 53.20% of users gave Moderna an outperform vote.
In the previous week, Moderna had 13 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 34 mentions for Moderna and 21 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 1.13 beat Moderna's score of 0.62 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to Moderna's net margin of -110.04%. MoonLake Immunotherapeutics' return on equity of -15.54% beat Moderna's return on equity.
75.3% of Moderna shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 11.0% of Moderna shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Moderna currently has a consensus target price of $53.58, indicating a potential upside of 100.52%. MoonLake Immunotherapeutics has a consensus target price of $78.71, indicating a potential upside of 104.40%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Moderna.
MoonLake Immunotherapeutics has lower revenue, but higher earnings than Moderna. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
Summary
MoonLake Immunotherapeutics beats Moderna on 12 of the 18 factors compared between the two stocks.
Get MoonLake Immunotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MoonLake Immunotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLTX) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy MLTX Stock Free MLTX Stock Alerts